Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13522411 | 0.87 | HTT (0.76) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL13522415 | 0.87 | HTT (0.60) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL28487208 | 0.86 | GPBAR1 (0.70) | HTTGPBAR1TSHRTP53ADORA3 | |
| SCHEMBL880467 | 0.86 | HTT (0.78) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL10280315 | 0.86 | HTT (0.78) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL3891266 | 0.86 | HTT (0.78) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL17782158 | 0.84 | TP53 (0.72) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL13522409 | 0.84 | HTT (0.64) | HTTPKMGPBAR1TSHRTP53 | |
| SCHEMBL3895171 | 0.84 | HTT (0.67) | HTTPKMGPBAR1TSHRLMNA | |
| SCHEMBL3887529 | 0.83 | HTT (0.73) | HTTPKMGPBAR1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1802303-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY | WHITEHEAD BIOMEDICAL INST (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110105496-A1 | Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds | GILEAD COLORADO, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090306373-A1 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | GILEAD COLORADO, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1965796-A2 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Gilead Colorado, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007089548-A2 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007076379-A2 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | GILEAD COLORADO, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | HTT 3/4885PKM 572/4885GPBAR1 3453/4885 |
| US-20090306373-A1 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | MYH2, TNNT2, MYLK2 | HTT 482/4885PKM 583/4885GPBAR1 652/4885 |
| US-20110105496-A1 | Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds | MYH2, MYLK2, TNNI3 | HTT 459/4885PKM 1340/4885GPBAR1 1494/4885 |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | HTT 207/4885PKM 2750/4885GPBAR1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.